Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).
作者信息
Lin Tzu-Yi, Kang Eugene Yu-Chuan, Shao Shih-Chieh, Lai Edward Chia-Cheng, Hwang Yih-Shiou
机构信息
Department of Education, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.
出版信息
Diabetes Metab J. 2023 Jul;47(4):573-574. doi: 10.4093/dmj.2023.0188. Epub 2023 Jul 27.
Abstract
摘要
相似文献
1
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂之间糖尿病视网膜病变的风险（《糖尿病代谢杂志》2023年；47:394-404）
Diabetes Metab J. 2023 Jul;47(4):573-574. doi: 10.4093/dmj.2023.0188. Epub 2023 Jul 27.
2
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂之间糖尿病视网膜病变的风险（《糖尿病与代谢杂志》2023年；47:394-404）
Diabetes Metab J. 2023 Jul;47(4):571-572. doi: 10.4093/dmj.2023.0164. Epub 2023 Jul 27.
3
Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂治疗：糖尿病视网膜病变后遗症的不同观察结果
J R Soc Med. 2023 Dec;116(12):408. doi: 10.1177/01410768231215999. Epub 2023 Dec 6.
4
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病的视网膜病变风险。
Diabetes Metab J. 2023 May;47(3):394-404. doi: 10.4093/dmj.2022.0221. Epub 2023 Mar 6.
5
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230007. doi: 10.7326/L23-0007.
6
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230005. doi: 10.7326/L23-0005.
7
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230006. doi: 10.7326/L23-0006.
8
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
9
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.胰高血糖素样肽-1 受体激动剂与心力衰竭：进一步生成证据和优化实践指南的必要性。
Circulation. 2020 Sep 22;142(12):1205-1218. doi: 10.1161/CIRCULATIONAHA.120.045888. Epub 2020 Sep 21.
10
Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.胰高血糖素样肽 1 受体激动剂 (GLP1RA) 和钠-葡萄糖共转运蛋白 2 抑制剂 (SGLT2i)：在糖尿病管理中做出务实的选择。
J Pak Med Assoc. 2022 May;72(5):989-990. doi: 10.47391/JPMA.22-64.
引用本文的文献
1
Peptides based on the interface of hnRNPA2B1-transthyretin complex repress retinal angiogenesis in diabetic retinopathy.基于异质性核糖核蛋白A2B1-转甲状腺素蛋白复合物界面的肽可抑制糖尿病视网膜病变中的视网膜血管生成。
J Transl Med. 2025 Apr 19;23(1):458. doi: 10.1186/s12967-025-06437-y.
本文引用的文献
1
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病的视网膜病变风险。
Diabetes Metab J. 2023 May;47(3):394-404. doi: 10.4093/dmj.2022.0221. Epub 2023 Mar 6.
2
An introduction to inverse probability of treatment weighting in observational research.观察性研究中治疗权重逆概率法简介。
Clin Kidney J. 2021 Aug 26;15(1):14-20. doi: 10.1093/ckj/sfab158. eCollection 2022 Jan.
3
Sensitivity Analysis in Observational Research: Introducing the E-Value.观察性研究中的敏感性分析：引入 E 值。
Ann Intern Med. 2017 Aug 15;167(4):268-274. doi: 10.7326/M16-2607. Epub 2017 Jul 11.
4
Epidemiology of type 1 diabetes.1 型糖尿病的流行病学。
Endocrinol Metab Clin North Am. 2010 Sep;39(3):481-97. doi: 10.1016/j.ecl.2010.05.011.
Zotero 插件